Ratings by Piper Sandler (Kelsey Goodwin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/27/2026 | LeonaBio | LONA | New Coverage | Overweight (N/A) |
10.33 (8.63) |
-16.46% | Details | |
| 5/15/2026 | Tango Therapeutics Inc. | TNGX | Downgrade | Neutral (Overweight) |
25.51 (21.47) |
-15.84% | Details | |
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/24/2026 | Relmada Therapeutics Inc | RLMD | New Coverage | Overweight (N/A) |
6.07 (6.33) |
4.28% | Details | |
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Neutral (Overweight) |
12.78 (21.53) |
68.47% | Details | |
| 2/26/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Erasca Inc | ERAS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Black Diamond Therapeutics | BDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2026 | Protera Therapeutics | TARA | New Coverage | Overweight (N/A) |
5.39 (4.22) |
-21.71% | Details | |
| 1/7/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Overweight (N/A) |
8.15 (7.84) |
-3.8% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Overweight (N/A) |
25.10 (10.51) |
-58.13% | Details | |
| 1/7/2026 | Erasca Inc | ERAS | New Coverage | Overweight (N/A) |
3.49 (13.18) |
277.65% | Details | |
| 11/17/2025 | Black Diamond Therapeutics | BDTX | New Coverage | Overweight (N/A) |
4.01 (2.10) |
-47.63% | Details | |
| 11/5/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/19/2025 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
75.01 (90.18) |
20.22% | Details | |
| 8/19/2025 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
6.77 (25.51) |
276.81% | Details | |
| 8/19/2025 | UroGen Pharma | URGN | New Coverage | Overweight (N/A) |
19.71 (26.60) |
34.96% | Details | |
| 8/19/2025 | Summit Therapeutics plc | SMMT | New Coverage | Neutral (N/A) |
26.69 (15.07) |
-43.54% | Details | |
| 8/19/2025 | Revolution | RVMD | New Coverage | Overweight (N/A) |
36.32 (155.99) |
329.49% | Details | |
| 8/19/2025 | Janux Therapeutics | JANX | New Coverage | Overweight (N/A) |
25.11 (13.59) |
-45.88% | Details | |
| 8/19/2025 | Day One Biopharmaceuticals | DAWN | New Coverage | Overweight (N/A) |
52.88 (12.78) |
-75.83% | Details | |
| 8/19/2025 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
25.70 (54.42) |
111.75% | Details | |
| 8/19/2025 | Bicara Therapeutics Inc | BCAX | New Coverage | Overweight (N/A) |
11.64 (20.00) |
71.82% | Details |
